Clinical Trials on Genetic Loci in Japan

Total 468 results

Mylan Inc.

Completed

Special Investigation (All Cases) of LipaCreon in Patients With Pancreatic Exocrine Insufficiency Due to Cystic Fibrosis

Digestive System Diseases | Pancreatic Diseases | Cystic Fibrosis | Exocrine Pancreatic Insufficiency

Japan
Novartis Pharmaceuticals

Completed

An Extention Study of Safety of Canakinumab in Japanese Patients With Periodic Fever Syndromes

Periodic Fevers Syndrome

Japan
Eli Lilly and Company

Completed

A Study of Lebrikizumab (LY3650150) in Combination With Topical Corticosteroids in Japanese Participants With Moderate-to-Severe Atopic Dermatitis (ADhere-J)

Skin Diseases | Skin Diseases, Genetic | Dermatitis | Eczema | Dermatitis, Atopic

Japan
Sanofi
Regeneron Pharmaceuticals

Completed

Dupilumab in Japanese Patients With Atopic Dermatitis

Atopic Dermatitis

Japan
Novo Nordisk A/S

Completed

Investigating the Long-term Efficacy and Safety of Two Doses of NN-220 (Somatropin) in Short Stature Due to Noonan Syndrome

Noonan Syndrome | Genetic Disorder

Japan
Novartis Gene Therapies
PRA Health Sciences

Completed

Single-Dose Gene Replacement Therapy Using for Patients With Spinal Muscular Atrophy Type 1 With One or Two SMN2 Copies

Spinal Muscular Atrophy Type I

Korea, Republic of, Taiwan, Japan
Boehringer Ingelheim

Completed

A Study in Patients With Atopic Eczema to Test How Effective BI 655130 is and How Well it is Tolerated

Dermatitis, Atopic

United States, Japan, Canada
Baxalta now part of Shire

Completed

A Study of Immune Globulin Subcutaneous (Human), 20% Solution (IGSC, 20%) in Japanese Participants With Primary Immunodeficiency Diseases (PID)

Primary Immunodeficiency Diseases (PID)

Japan
Translational Research Center for Medical Innovation...

Terminated

Clinical Study on the Safety of CNT-02 for TGCV and NLSD-M

Primary Triglyceride Deposit Cardiomyovasculopathy (TGCV) | Neutral Lipid Storage Disease With Myopathy (NLSD-M)

Italy, Japan
Novo Nordisk A/S

Enrolling by invitation

Post-Marketing Surveillance (Use-results Surveillance) With Esperoct®

Haemophilia A

Japan
Baxalta now part of Shire

Completed

Pivotal Study (Pharmacokinetics, Efficacy, Safety) of BAX 326 (rFIX) in Hemophilia B Patients

Hemophilia B

Poland, United Kingdom, Spain, Bulgaria, Romania, Japan, Russian Federation, Brazil, Chile, Sweden, Colombia, Ukraine, Argentina, Czechia
Takeda

Completed

Study of TAK-672 in Participants With Acquired Hemophilia A

Acquired Hemophilia A

Japan
Baxalta now part of Shire

Completed

Efficacy and Safety Study of Prophylactic Versus On-Demand Treatment With Feiba NF in Subjects With Hemophilia A or B and a High Titer Inhibitor

Hemophilia A | Hemophilia B | Hemophilia A or B With Inhibitors

Poland, United States, Bulgaria, Romania, Japan, Russian Federation, New Zealand, Croatia, Ukraine, Brazil
LEO Pharma

Completed

Tralokinumab in Combination With Topical Corticosteroids in Japanese Subjects With Moderate-to-severe Atopic Dermatitis (ECZTRA 8)

Atopic Dermatitis

Japan
Takeda

Active, not recruiting

A Study of TAK-625 for the Treatment of Alagille Syndrome (ALGS)

Alagille Syndrome (ALGS)

Japan
Kobe University
Boehringer Ingelheim

Active, not recruiting

A Study of Empagliflozin in Patients With Refractory Diabetes Mellitus With Insulin Resistance (EMPIRE-01)

Insulin Resistance - Type A | Insulin Resistance - Type B | Lipoatrophic Diabetes Mellitus | Insulin Resistance Syndrome

Japan
Kobe University
Boehringer Ingelheim

Active, not recruiting

A Extension Study of Empagliflozin in Patients With Refractory Diabetes Mellitus With Insulin Resistance ( EMPIRE-02 ) (EMPIRE-02)

Insulin Resistance - Type A | Insulin Resistance - Type B | Lipoatrophic Diabetes Mellitus | Insulin Resistance Syndrome

Japan
CSL Behring

Completed

A Safety and Efficacy Study of a Recombinant Fusion Protein Linking Coagulation Factor IX With Albumin (rIX-FP) in Patients With Hemophilia B

Hemophilia B

United States, Japan, Israel, Austria, Bulgaria, France, Germany, Italy, Russian Federation, Spain
Kyowa Kirin, Inc.
Kyowa Kirin Co., Ltd.

Completed

Study of an Anti-OX40 Monoclonal Antibody (KHK4083) in Subjects With Moderate to Severe Atopic Dermatitis

Atopic Dermatitis

United States, Canada, Germany, Japan
Pfizer

Completed

Crisaborole for Chinese and Japanese Subjects (≥2 Years of Age) With Mild to Moderate Atopic Dermatitis

Atopic Dermatitis

China, Japan, Korea, Republic of
AstraZeneca
Ardea Biosciences, Inc.

Completed

Phase II Dose Finding Study of RDEA3170 Versus Placebo in Japanese Patients With Gout or Asymptomatic Hyperuricemia

Gout and Hyperuricemia

Japan
Pfizer

Completed

Study Evaluating SKI-606 (Bosutinib) In Japanese Subjects With Philadelphia Chromosome Positive Leukemias

Chronic Myelogenous Leukemia

Japan
Janssen Research & Development, LLC

Terminated

A Study of Bermekimab (JNJ-77474462) in the Treatment of Participants With Moderate to Severe Atopic Dermatitis (GENESIS)

Dermatitis, Atopic

United States, Germany, Canada, Poland, Japan
Mitsubishi Tanabe Pharma America Inc.

Recruiting

INcreased Sun Exposure Without Pain In Research Participants With EPP or XLP (INSPIRE)

Erythropoietic Protoporphyria (EPP) | X-Linked Protoporphyria (XLP)

United States, Spain, France, Japan, United Kingdom, Italy, Australia, Poland, Bulgaria, Czechia, Netherlands
Otsuka Pharmaceutical Co., Ltd.

Completed

A Study to Investigate the Long-term Safety and Efficacy of Tolvaptan in Patients With Autosomal Dominant Polycystic Kidney Disease (ADPKD) [Extension of Trial 156-04-251 in Japan]

Autosomal Dominant Polycystic Kidney Disease （ADPKD)

Japan
Bayer

Completed

Patient Functioning and Well-being, Economic, and Clinical Impact of Hemophilia A and Its Treatment (ECHO)

Hemophilia A

United States, Japan, United Kingdom, Spain
Takeda

Completed

Expanded Access Program With Lanadelumab for Japanese People With Hereditary Angioedema

Hereditary Angioedema

Japan
Pfizer

Terminated

An Open-label Extension Study To Evaluate Safety Of PF-06252616 In Boys With Duchenne Muscular Dystrophy

Duchenne Muscular Dystrophy

United States, Canada, United Kingdom, Japan, Italy
Dicerna Pharmaceuticals, Inc., a Novo Nordisk company

Enrolling by invitation

Long Term Extension Study in Patients With Primary Hyperoxaluria (PHYOX3)

Kidney Diseases | Urologic Diseases | Genetic Disease | Primary Hyperoxaluria Type 1 (PH1) | Primary Hyperoxaluria Type 2 (PH2) | Primary Hyperoxaluria Type 3 (PH3)

United States, France, Germany, Japan, Lebanon, Spain, United Kingdom, Australia, Canada, Italy, Netherlands, Norway, Turkey
Novo Nordisk A/S

Completed

Safety of 40K Pegylated Recombinant Factor IX in Non-Bleeding Patients With Haemophilia B

Congenital Bleeding Disorder | Haemophilia B

United States, Sweden, Spain, Germany, United Kingdom, Denmark, France, Japan
CSL Behring

Completed

Multicenter Study of Long-Term Clinical Outcomes of Subcutaneous Immune Globulin IgPro20 in Subjects With Primary Immunodeficiency (Japan Study)

Primary Immune Deficiency

Japan
CSL Behring

Completed

Study of Subcutaneous Immune Globulin in Patients Requiring IgG Replacement Therapy (Japan Study)

Primary Immune Deficiency

Japan
NS Pharma, Inc.
Nippon Shinyaku Co., Ltd.

Active, not recruiting

Study to Assess the Safety and Efficacy of Viltolarsen in Ambulant Boys With DMD (RACER53-X)

Duchenne Muscular Dystrophy

Korea, Republic of, Chile, Japan, China, United Kingdom, Netherlands, Spain, Norway, Russian Federation, Australia, Greece, Italy, New Zealand, Turkey, Mexico, Czechia, Canada
Novartis Pharmaceuticals

Terminated

Prospective, Observational Study in Sickle Cell Disease Patients on Crizanlizumab Treatment in Middle East Countries and India (SPOTLIGHT)

Sickle Cell Disease

United Arab Emirates, Bahrain, Kuwait, Qatar, Saudi Arabia
Chugai Pharmaceutical

Not yet recruiting

Phase 1b Trial of RAY121 in Immunological Diseases (RAINBOW Trial)

Antiphospholipid Syndrome (APS) | Immune Thrombocytopenia (ITP) | Dermatomyositis (DM) | Bullous Pemphigoid (BP) | Behçet's Syndrome (BS) | Immune-mediated Necrotizing Myopathy (IMNM)

United States, Japan
AbbVie

Completed

A Study to Evaluate ABT-494 (Upadacitinib) in Adults With Moderate to Severe Atopic Dermatitis

Atopic Dermatitis

United States, Australia, Canada, Finland, Germany, Japan, Netherlands, Spain
Novo Nordisk A/S

Completed

A Single Dose Trial of Recombinant Factor VIII (N8) in Japanese Subjects With Haemophilia A: An Extension to Trial NN7008-3543

Congenital Bleeding Disorder | Haemophilia A

Japan
CSL Behring

Completed

Follow-up Study of Subcutaneous Immune Globulin in Patients Requiring IgG Replacement Therapy (Japan Study)

Primary Immune Deficiency Disorder

Japan
Boston University
National Institute of Neurological Disorders and Stroke (NINDS); Food and Drug...

Completed

The Effect of Diflunisal on Familial Amyloidosis

Familial Amyloid Polyneuropathy | Familial Amyloidosis

United States, Italy, Japan, Sweden, United Kingdom
Novo Nordisk A/S

Completed

A Study to Evaluate DCR-PHXC in Children and Adults With Primary Hyperoxaluria Type 1 and Primary Hyperoxaluria Type 2 (PHYOX2)

Kidney Diseases | Urologic Diseases | Genetic Disease | Primary Hyperoxaluria Type 1 (PH1) | Primary Hyperoxaluria Type 2 (PH2)

Poland, United States, United Kingdom, New Zealand, Australia, Canada, France, Germany, Israel, Italy, Japan, Lebanon, Netherlands, Romania, Spain
Ministry of Health, Labour and Welfare, Japan

Unknown

Efficacy and Safety Study of Second-Line Treatment for Hypertension With Autosomal Dominant Polycystic Kidney Disease(ADPKD)

Kidney, Polycystic, Autosomal Dominant

Japan
Baxalta now part of Shire

Completed

BAX 326 (rFIX) Continuation Study

Hemophilia B

Taiwan, Colombia, Argentina, Brazil, Bulgaria, Chile, Czechia, India, Ireland, Italy, Japan, Poland, Romania, Russian Federation, Sweden, Ukraine, United Kingdom
Amgen

Completed

Efficacy and Safety Study of Apremilast in Subjects With Moderate to Severe Atopic Dermatitis

Dermatitis, Atopic Dermatitis

Canada, United States, Japan
Rege Nephro Co., Ltd.

Recruiting

Study of Tamibarotene in Patients With ADPKD

Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Japan
AbbVie

Completed

A Study to Evaluate Safety of Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis (Rising Up)

Atopic Dermatitis

Japan
Sarepta Therapeutics, Inc.
Hoffmann-La Roche

Recruiting

A Gene Transfer Therapy Study to Evaluate the Safety and Efficacy of Delandistrogene Moxeparvovec (SRP-9001) in Non-Ambulatory and Ambulatory Participants With Duchenne Muscular Dystrophy (DMD) (ENVISION)

Duchenne Muscular Dystrophy

Belgium, United States, Japan, Spain, Italy, United Kingdom
Mitsubishi Tanabe Pharma America Inc.

Active, not recruiting

Extension Study to Evaluate Safety and Tolerability of Oral Dersimelagon (MT-7117) in Subjects With Erythropoietic Protoporphyria (EPP) or X-Linked Protoporphyria (XLP)

EPP | XLP

United States, Germany, Japan, Spain, Italy, Sweden, Australia, Canada, Norway, United Kingdom
Novo Nordisk A/S

Completed

Pharmacogenetic Testing of Saliva Samples From Patients With Five or More Exposure Days to rFVIIa Analogue in the Adept™2 Trial

Congenital Bleeding Disorder | Haemophilia A With Inhibitors | Haemophilia B With Inhibitors

United States, Serbia, Malaysia, Thailand, Greece, Japan, Romania
JW Pharmaceutical
LEO Pharma

Completed

Efficacy and Safety of LEO 152020 Tablets for the Treatment of Adults With Moderate to Severe Atopic Dermatitis

Atopic Dermatitis

United States, Canada, Czechia, Germany, Poland, Spain, Australia, Japan
Bioverativ, a Sanofi company

Completed

A Safety, Tolerability, and Pharmacokinetics Study of a Single Intravenous Injection of Recombinant Coagulation Factor VIII Fc - Von Willebrand Factor - XTEN Fusion Protein (rFVIIIFc-VWF-XTEN) (BIVV001) in Previously Treated Adults With Severe Hemophilia A (EXTEN-A)

Hemophilia A

United States, Japan

Clinical Trials on Genetic Loci in Japan

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Senegal

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations